Key result
Biochemical markers of myocyte injury, such as cTnT, cTnI, H-FABP, and MLC-1, increase in the absence of ischaemic events in heart failure patients with the most adverse long-term outcomes.
Why the study?
Does the measurement of biochemical markers of myocyte injury predict adverse long-term outcomes in patients with chronic congestive heart failure?
Does the measurement of biochemical markers of myocyte injury predict adverse long-term outcomes in patients with chronic congestive heart failure?
Serial measurement of biochemical markers of myocyte injury can help identify chronic heart failure patients at risk for adverse long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Marker elevations may aid risk stratification in non-ischaemic HF; hypothesis-generating for prospective trials.
Yukihito Sato (2004) conducted a review in chronic congestive heart failure. Biochemical markers of myocyte injury (cTnT, cTnI, H-FABP, MLC-1) was evaluated. Biochemical markers of myocyte injury, such as cTnT, cTnI, H-FABP, and MLC-1, increase in the absence of ischaemic events in heart failure patients with the most adverse long-term outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: